Hiv Aids

NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess

South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme's first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck's once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

How is South Africa advancing local production of cutting-edge HIV treatments? The country has shortlisted manufacturers for Lenacapavir, paving the way for greater domestic capacity, improved access, and stronger pharmaceutical supply chains across the region. Explore how this step supports broader drug development goals. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

Is Africa's HIV future at a crossroads? The Africa HIV Control Working Group's 2026 webinar spotlighted UNAIDS, UNICEF & health leaders on domestic financing, sovereignty, integrated systems & community leadership to build resilient HIV control. Read more & join the push for bold action. #HIVControl #AfricaHealth #BoldLeadership #UNAIDS #GlobalHealth

How can smart licensing cut years off HIV prevention launches in Africa? Aspen’s latest agreements are shrinking launch lags by enabling faster local production and regulatory pathways for prevention therapies. This approach is expanding access where it’s needed most. Read the full story on how these deals are reshaping timelines and equity in HIV care. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #innovation

💊 Could once-weekly dosing redefine HIV treatment adherence? A new trial confirms that islatravir combined with lenacapavir delivers sustained viral suppression, offering a promising step toward simpler, longer-acting regimens for people living with HIV. Read the full analysis and implications for drug development. #SyenzaNews #clinicaltrials #pharmaceuticals #innovation

💊 How are pharmacists expanding HIV treatment access across South Africa? Through the PIMART initiative, trained pharmacists can now initiate antiretroviral therapy, closing critical gaps in care and reaching more patients in underserved communities. Discover how this model is reshaping service delivery and outcomes. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #innovation

Can public–private partnerships finally close the gap in HIV treatment access? 🤝 This article explores how PPPs can streamline drug integration—aligning procurement, supply chains, financing and regulation—to expand timely, affordable HIV care. It highlights practical success factors (clear governance, data integration, sustainable financing) and policy steps to scale these models. Read the full piece to see actionable lessons for policymakers, donors, and private partners. #SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess #healthcarepolicy

Could weekly HIV treatments be the game-changer for adherence and access? 💊🔬 Emerging long‑acting formulations and novel dosing strategies aim to simplify regimens, reduce clinic visits, and broaden treatment reach — with important implications for patients, payers, and health systems. Read the full article to explore the latest candidates, evidence, and what weekly dosing could mean for global HIV care. #SyenzaNews #drugdevelopment #globalhealth #innovation #healthcarepolicy

Can South Africa finally close the gap in HIV prevention access? 🌍 This piece maps the barriers—stigma, service gaps, supply-chain and funding shortfalls—and highlights practical, evidence-based strategies: PrEP scale-up, community- and youth-led delivery, primary care integration, task-shifting, and data-driven targeting to reach underserved populations. Read the full article for actionable recommendations and policy priorities to accelerate equitable HIV prevention nationwide. #SyenzaNews #globalhealth #HealthEconomics #healthcarepolicy #MarketAccess

🌍 How is South Africa shaping the future of health through innovative research? The South African Medical Research Council is taking strides in addressing critical health challenges by integrating biomedical and social sciences, enhancing vaccine production, and improving HIV management. Under the leadership of CEO Ntobeko Ntusi, these efforts promise to bolster local innovation and scientific capacity. Don't miss the chance to dive deeper into their transformative strategies and priorities! #SyenzaNews #HealthcareInnovation #globalhealth #innovation